OmniAb Inc (OABI) (Q3 2026) Earnings Call Highlights: Lilly Deal, Raised Guidance
OmniAb Inc (OABI) reported Q3 2026 earnings, highlighting raised guidance and a busy pipeline. Milestones remain the largest revenue contributor, with royalties expected to grow from IMVT-1402 in late 2028. Exploration revenue is projected to double in 2027 and 2028. The company expects $340M in potential milestones from active clinical programs. OmniTides, a new peptide workflow, is attracting partner interest. Bataclimab's royalty contribution in China is uncertain pending launch details.
How this was made
The 30-second read
Why it matters
Guidance raise and milestone pipeline suggest upside for the stock, but execution risk remains.
Market read
New guidance and milestone outlook provide fresh material for traders evaluating OABI.
What to watch
Potential regulatory delays for IMVT-1402 and reliance on partner capital cycles.
Background
OmniAb held its Q3 2026 earnings call, discussing revenue mix, milestones, and future growth drivers.
Ticker impact
Management provided new guidance on milestones, royalty potential and revenue growth through 2028, including $340M remaining milestones and doubled revenue targets.
likely upward pressure as investors price in higher future royalties and revenue growth
Guidance exceeds prior expectations and highlights new revenue streams, which typically drives buying interest.
Market effects
Positive outlook may lift peer biotech and contract research organizations.
U.S. biotech sector could see modest gains.
Limited to biotech investors; no broad market impact.
Counterpoint
If milestone execution delays, guidance may be overly optimistic.
Key entities
- CompanyOmniAb Inc
Biotech firm providing antibody discovery platforms.
- PartnerLilly
Collaborator on ion channel deal mentioned in the call.
